jpm_asset_mgmt
  • Products

    Funds

    • Performance & Yields
    • Liquidity
    • Ultra-Short
    • Short Duration

    Solutions

    • Cash Segmentation
    • Separately Managed Accounts
    • Managed Reserves Strategy
  • Insights

    Liquidity Insights

    • Liquidity Insights Overview
    • Audio Commentaries
    • Case Studies
    • Leveraging the Power of Cash Segmentation
    • Cash Investment Policy Statement
    • China Money Market Resource Centre
    • PeerView Survey

    Market Insights

    • Market Insights Overview
    • Eye on the Market
    • Guide to the Markets
    • Market Updates

    Portfolio Insights

    • Portfolio Insights Overview
    • Currency
    • Fixed Income
    • Long-Term Capital Market Assumptions
    • Sustainable Investing
  • Resources
    • MORGAN MONEY
    • Account Management & Trading
    • Multimedia
    • Announcements
  • About us
  • Contact us
Skip to main content
  • English
  • Role
  • Country
  • MORGAN MONEY LOGIN
Search
Menu
CLOSE
Search
You are about to leave the site Close
J.P. Morgan Asset Management’s website and/or mobile terms, privacy and security policies don't apply to the site or app you're about to visit. Please review its terms, privacy and security policies to see how they apply to you. J.P. Morgan Asset Management isn’t responsible for (and doesn't provide) any products, services or content at this third-party site or app, except for products and services that explicitly carry the J.P. Morgan Asset Management name.
CONTINUE Go Back
  1. Home
  2. Insights
  3. Market Insights Overview
  4. Eye on the Market
  5. Coronavirus research

  • Share
  • LinkedIn Twitter Facebook
  • Email
  • Print
  • Actions
  • LinkedIn Twitter Facebook
    Email Print

Coronavirus (COVID-19) research

April 2021

Michael Cembalest

This compilation includes all of our research to-date on the coronavirus. High frequency charts on infection, mortality, economic and market data are updated as data becomes available, usually on a daily basis.

What’s new: Early tracking of variants and vaccine efficacy (Section 4); Vaccination update by country and US state (Section 4); Reinfection risks in previously infected populations (Section 5).

To hear more of Michael Cembalest’s thoughts on global markets and the economy, explore previous versions of Eye on the Market:

READ MORE BY MICHAEL CEMBALEST

Access Michael Cembalest’s COVID Charts of the Week:

VIEW NOW

Our research to-date on the coronavirus:


1. US spending, mobility, and production tracker ›
2. COVID global infection, hospitalization and mortality tracker ›
3. COVID tracker: countries and states ›
4. COVID vaccination update and drug development ›
5. COVID: reinfection, antibodies, T-cell immune memory and survivor impacts ›

1. US spending, mobility, and production tracker

  • High frequency tracking (manufacturing, retail, air travel, geolocation, oil, hotels, housing, etc.)
  • Office utilization rates and mobility
  • Real time credit and debit spending data

READ MORE


2. COVID global infection, hospitalization and mortality tracker

  • Commentary and charts on the latest COVID trends by country and region
  • Global and regional snapshots, comparisons of largest countries and US states
  • How lethal is COVID, and for whom?

READ MORE


3. COVID tracker: countries and states 

  • Country and state specific charts on Infection, hospitalization and mortality

READ MORE


4. COVID vaccination update

  • Early tracking of variants and vaccine efficacy
  • Where does herd immunity kick in?
  • Vaccination update by country and US state
  • How mRNA vaccines, vector vaccines and traditional vaccine types work

READ MORE


5. COVID: reinfection, antibodies, T-cell immune memory and survivor impacts 

  • Reinfection risks in previously infected populations
  • COVID health impacts on survivors
  • How virus testing and antibody testing work 
  • Pre-existing T-cell immune memory and COVID
  • The issue of falling antibody levels in convalescing patients
  • The latest news on anti-virals, monoclonal antibodies, convalescent plasma and corticosteroids

READ MORE

This compilation incorporates research and feedback from the Johns Hopkins University Center for Health Security, Harvard Medical School, the University of Toronto Dalla Lana School of Public Health, Washington University Biomedical Sciences Department, the La Jolla Institute for Immunology, the Imperial College of London Department of Infectious Disease Epidemiology and the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.


0903c02a8283f910

Listen and Subscribe

 

Listen on Apple Podcasts ›

Subscribe to RSS Feed ›

   

 

Get the latest commentaries in your inbox ›

Follow Michael Cembalest on LinkedIn ›

Markets Volatility Eye on the Market
J.P. Morgan Asset Management

  • Investment stewardship
  • About us
  • Contact us
  • Privacy policy
  • Cookie policy
  • Binding corporate rules
  • Sitemap
Decorative
J.P. Morgan

  • J.P. Morgan
  • JPMorgan Chase
  • Chase

READ IMPORTANT LEGAL INFORMATION. CLICK HERE >

The value of investments may go down as well as up and investors may not get back the full amount invested.

Copyright 2021 JPMorgan Chase & Co. All rights reserved.